Back to Search
CHELSEA GRUBBS, PHARMD
PHARMD
Pharmacist
NPI: 1477168367Individual
Specialties, Licenses & Credentials
PharmacistPrimary
Pharmacist
Code: 183500000X
021128(KY)
Research & Publications (20)
High Cks1 expression in transgenic and carcinogen-initiated mammary tumors is not always accompanied by reduction in p27Kip1.
PMID 19360356·Int J Oncol·2009
7-preclinical
Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis.
PMID 19196723·Cancer Prev Res (Phila)·2009
4-observational
Prevention of KLF4-mediated tumor initiation and malignant transformation by UAB30 rexinoid.
PMID 19197145·Cancer Biol Ther·2009
7-preclinical
Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers.
PMID 18712722·Int J Cancer·2008
7-preclinical
Effect of cranberry juice concentrate on chemically-induced urinary bladder cancers.
PMID 18497966·Oncol Rep·2008
7-preclinical
Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes.
PMID 18375820·Mol Cancer Ther·2008
7-preclinical
Short-term modulation of cell proliferation and apoptosis and preventive/therapeutic efficacy of various agents in a mammary cancer model.
PMID 17875779·Clin Cancer Res·2007
7-preclinical
Preventive effects of polyphenon E on urinary bladder and mammary cancers in rats and correlations with serum and urine levels of tea polyphenols.
PMID 17620432·Mol Cancer Ther·2007
7-preclinical
Gene expression profiling of chemically induced rat bladder tumors.
PMID 17401461·Neoplasia·2007
7-preclinical
Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: prevention, therapy, and role of HaRas mutations.
PMID 16648579·Mol Cancer Ther·2006
7-preclinical
Organ-specific expression profiles of rat mammary gland, liver, and lung tissues treated with targretin, 9-cis retinoic acid, and 4-hydroxyphenylretinamide.
PMID 16648578·Mol Cancer Ther·2006
7-preclinical
Efficacy of the farnesyltransferase inhibitor R115777 in a rat mammary tumor model: role of Ha-ras mutations and use of microarray analysis in identifying potential targets.
PMID 16403772·Carcinogenesis·2006
7-preclinical
Efficacy of new retinoids in the prevention of mammary cancers and correlations with short-term biomarkers.
PMID 16344269·Carcinogenesis·2006
7-preclinical
Efficacy of Targretin on methylnitrosourea-induced mammary cancers: prevention and therapy dose-response curves and effects on proliferation and apoptosis.
PMID 15591091·Carcinogenesis·2005
7-preclinical
Hypermethylation patterns in the Fhit regulatory region are tissue specific.
PMID 15937960·Mol Carcinog·2005
7-preclinical
Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer.
PMID 15750629·Oncogene·2005
7-preclinical
4-Hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers in mice: characterization of FHIT and survivin expression and chemopreventive effects of indomethacin.
PMID 15591090·Carcinogenesis·2005
7-preclinical
Chemoprevention by grape seed extract and genistein in carcinogen-induced mammary cancer in rats is diet dependent.
PMID 15570052·J Nutr·2004
7-preclinical
Proteomics analysis of rat brain protein modulations by grape seed extract.
PMID 15612770·J Agric Food Chem·2004
7-preclinical
Cancer chemopreventive activity of a mixture of Chinese herbs (antitumor B) in mouse lung tumor models.
PMID 15021904·Oncogene·2004
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 152 N BUCKMAN ST
SHEPHERDSVILLE, KY 40165 - Phone
- (502) 543-2202
Quick Facts
- NPI
- 1477168367
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile